CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0874 (clinicaltrials.gov NCT No: NCT01396499)
Title:A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K kinase inhibitor, in Patients with Advanced Leukemias
Principal Investigator:Marina Konopleva
Treatment Agent:BKM120
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of BKM120 that can be given to patients with relapsed or refractory leukemia.
The safety of BKM120 will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:BKM120
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
Dept:Leukemia
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults